Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis

Jian Cao1,2*, Xuan Zhu1*, Xiaokun Zhao1, Xue-Feng Li2, Ran Xu1

1 Department of Urology, The Second Xiangya Hospital, Central South University, Hunan Province, People’s Republic of China, 2 MRC Centre for Reproductive Health, Queen’s Medical Research Institute, Edinburgh, United Kingdom

☯ These authors contributed equally to this work.
* ddf20@sina.com

Abstract

An unprecedented advance has been seen in castration-resistant prostate cancer (CRPC) treatments in the past few years. With a number of novel agents were approved, there is a pressing need to develop improved prognostic biomarkers to facilitate the personalised selection and sequencing of these novel agents. Emerging evidence indicates that the neutrophil-to-lymphocyte ratio (NLR) is associated with poorer survival in patients with prostate cancer (PCa). However, the importance of the NLR for the prediction of the PSA response (PSARS) and biochemical recurrence (BCR) has been largely neglected. Here, we conducted a systematic review and meta-analysis to evaluate the prognostic value of the NLR for the PSARS, BCR, and survival in PCa. A systematic database search was performed using Embase, PubMed, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI). A meta-analysis was performed by pooling hazard ratios (HRs), odds ratios (ORs) and the corresponding 95% confidence intervals (CIs). A total of 22 studies were included in the meta-analysis. Our results suggest that an elevated NLR predicts a lower PSARS rate (OR = 1.69, 95% CI: 1.40–1.98) and a higher possibility of BCR (HR = 1.12, 95% CI: 1.02–1.21). Additionally, we confirmed that an elevated NLR was a prognostic predictor of shorter overall survival (OS) in both metastatic castration-resistant PCa (mCRPC) (HR = 1.45, 95% CI: 1.32–1.59) and localized PCa (LPC) (HR = 1.12, 95% CI: 1.01–1.23) and that it predicted worse progression-free survival (PFS) in CRPC (HR = 1.42, 95% CI: 1.23–1.61) and poorer recurrence-free survival (RFS) (HR = 1.38, 95% CI: 1.01–1.75) in LPC. Our results suggest that an elevated NLR might be employed as a prognostic marker of biochemical changes and prognosis to facilitate risk stratification and decision making for individual treatment of PCa patients. The potential mechanisms underlying these associations and future research directions are also discussed.
Introduction

Prostate cancer (PCa) is a major health concern for the male population; PCa is the second most common cancer and the fifth leading cause of cancer-associated death in men worldwide [1]. Although PCa-specific mortality in the US and the UK has declined markedly since the 1990s[2], slow increases and stable mortality have been observed in other regions[3]. A steady increase in the incidence rate was observed from 1975 to the early 1990s owing to the widespread application of transurethral resection and PSA testing for PCa screening[4,5]. This increase was followed by a stable incidence trend with an increased rate among patients younger than 70 years[6].

The PSA test was a landmark development in the early diagnosis of prostate cancer. Because PSA (a glycoprotein secreted by the prostate gland) is organ-derived and elevated PSA may also be caused by benign prostatic hypertrophy, prostatitis and recent manipulations of the prostate (massage, urethroscopy or biopsy), there is no precise threshold for a normal PSA value. However, higher PSA levels are thought to be indicative of a greater likelihood of PCa [7]. Some PSA-related testing parameters (e.g., PSA density, free/total PSA ratio, PSA doubling time, and prostate health index test) have been used to improve the accuracy of PCa prediction [7]. PSA is also important for monitoring biochemical recurrence (BCR) after radical therapies and managing metastatic disease[8].

With a number of new drugs have been approved for CRPC in the past few years, personalised drug selection and sequencing of agents has become more challenging. Therefore, prognostic biomarkers reflecting the response of this disease to these novel agents are needed to guide clinical management. The host inflammatory response plays a significant role in tumor progression[9]. Many parameters are utilized to determine the inflammatory response status of patients; the neutrophil-to-lymphocyte ratio (NLR) is the most commonly used because it is easily accessible. Many clinical studies have demonstrated that an increased NLR is correlated with poor prognosis in prostate cancer, and it also predicts PSA responses under different drug treatments. However, the results of these studies are inconsistent. A recent meta-analysis indicated that an elevated NLR was correlated with worse OS and PFS in mCRPC patients; however, this study did not consider biochemical changes in PCa[10]. To derive a more precise estimate of the prognostic significance of the NLR, in this study, we performed a systematic review of the most recently published studies. The importance of the NLR in predicting OS, PSARS and BCR in PCa were established using standard meta-analysis techniques.

Materials and Methods

Search strategy

Systematic document retrieval was performed using PubMed, Embase, the Cochrane Library and China National Knowledge Infrastructure (CNKI) for all relevant studies without restrictions. To reduce heterogeneity, we also retrieved relevant studies written in Chinese from CNKI. Literature addressing the prognostic value of the NLR was searched by combining the following terms: (“neutrophil lymphocyte ratio” OR “neutrophil to lymphocyte ratio” OR “neutrophil-to-lymphocyte ratio” OR “NLR”) AND (“prostate neoplasm” OR “prostate carcinoma” OR “prostatic cancer” OR “prostatic neoplasm” OR “prostatic carcinoma”).

The last search was updated on February 11, 2016. The bibliographies of the relevant articles were also explored to identify any studies missed by the electronic search strategies. The search was independently conducted by two authors, and any discrepancies were resolved through group discussion and establishing a consensus.
Study selection and data extraction

After the removal of duplicates, two independent reviewers (including one urologist) screened the titles, abstracts, and full texts of all related articles using established criteria. The inclusion criteria were as follows: (a) confirmed diagnosis of PCa based on pathological examination; (b) evaluation of the prognostic value of the pretreatment NLR in PCa; (c) reported association between the NLR and PCa prognosis; and (d) reported HR, OR and 95% CI for prognosis or inclusion of data sufficient to estimate these statistics. The exclusion criteria were as follows: (a) reviews, case reports, letters, editorials, and animal and in vitro studies; (b) studies without sufficient data; (c) studies that did not include specific prognostic data concerning the NLR; and (d) articles written in languages other than Chinese or English.

The data were extracted using a reporting checklist proposed by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group[11]. The NLR value was calculated as the absolute neutrophil count divided by the absolute lymphocyte count obtained from a pre-treatment blood sample in all included studies. To date, there has been no validated cut-off value for NLR. In this meta-analysis, seven eligible studies defined elevated NLR as NLR ≥ 5 and five studies used NLR ≥ 3 as elevated NLR and two studies used NLR ≥ 2, another two studies used NLR ≥ 2.6 and ≥ 3.5 respectively. The BCR was defined as a PSA level ≥ 0.2 ng/ml in two consecutive tests. PSARS was defined as a PSA decline of ≥ 50% from baseline that was maintained for longer than 3 weeks. The HR, OR and 95% CI were obtained directly from each study or from reconstruction according to the methods described by Tierney et al[12]. The logarithm of the HR (logHR) was assumed to have a normal distribution. If CIs were reported, SEs for the logHRs were calculated. Engauge Digitizer (4.1) was used to read the Kaplan-Meier curves and extract data for reconstruction if the survival data were only provided in the form of figures. The data extraction was independently performed by two investigators, and any discrepancies were resolved by group discussion and consensus.

Statistical analysis

Standard meta-analysis methods[13] were applied to evaluate the overall effect of the NLR on the prognosis of PCa patients. Because the statistical methods (log-rank and Cox model) used in the eligible studies were inconsistent, the results were combined using the generic inverse variance method[13]. The consistency of the results (effect sizes) among studies was investigated using two heterogeneity tests: Cochran’s Q test and Higgins’s I-squared test. If heterogeneity was observed (Q test P value < 0.10 and I² > 50%), a meta-analysis was performed by applying the random-effects model[14]; otherwise, the fixed-effects model was applied.

Sensitivity to influential studies was evaluated by recalculating the pooled HRs after omitting each study from the meta-analysis consecutively (leave-one-out procedure). Subgroup analysis of the more homogeneous set of studies (i.e., those using the same stratification and study design features) was adopted as an additional sensitivity test.

Publication bias (i.e., negative trials are cited less frequently and therefore are more likely to be missed in the search for relevant studies) of the studies was analyzed using Begg’s funnel plot and Egger’s linear regression test. The “trim and fill” method was used to evaluate the influence of the missing publication on the overall effect[15]. Unless otherwise noted, no significant heterogeneity or publication bias was detected among the included studies. All statistical analyses were conducted with STATA version 12.0 software (STATA Corporation, College Station, TX, USA) and Revman version 5.3 software (Review Manager (RevMan) [Computer program]. Version [5.3]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). All statistical tests were two-sided, and the significance level was set at 5%.
**Results**

**Literature searches and study characteristics**

The selection flow of the relevant articles is shown in Fig 1. The initial search algorithm retrieved 131 studies. After removal of duplicates, two investigators independently screened the titles and abstracts of the remaining studies according to the predetermined criteria. Thirty-six studies remained after excluding case reports, reviews, editorials and irrelevant studies. After the full texts and bibliographies were screened, another 14 studies were removed owing to the inclusion of insufficient survival data for the meta-analysis. Thus, 22 relevant studies[16–37] published from 2012 to 2015 were included in the meta-analysis. The characteristics of the included studies are summarized in S1 Table.

In the 22 selected studies concerning the association between the NLR and PCa prognosis, 16 cohorts informed the link between the NLR and OS, seven studies investigated the NLR and RFS, six cohorts reported a link between the NLR and PFS, six cohorts provided correlations between the NLR and PSARS, five studies reported an association between the NLR and BCR (S1 Table). A meta-analysis was employed for each end point.

**NLR and PSARS in mCRPC**

Our meta-analysis detected a significant correlation between the NLR and PSARS. The pooled estimate from 6 cohorts indicated that patients with elevated pre-treatment NLRs tended to have 1.69-fold lower PSARSs after docetaxel- or cabazitaxel-based chemotherapy and androgen synthesis inhibitor (ASI) treatment (abiraterone or ketoconazole) compared to those patients with NLR below cut-off values(OR = 1.69, 95% CI: 1.40–1.98) (Table 1).

Subgroup analysis by therapy was conducted. The patients in the two cohorts received ASI, whereas chemotherapy agents such as docetaxel or cabazitaxel were administered in the remaining cohorts. The association of elevated pre-treatment NLRs with lower PSARS was replicated in the cohorts that received chemotherapy (OR = 1.68, 95% CI: 1.39–1.97). However, an elevated NLR was not significantly associated with PSARS in patients who received ASI (OR = 3.68, 95% CI: 0.37–6.99) (Fig 2A).

**NLR and BCR in PCa after radical prostatectomy**

Five studies investigated the association between an elevated NLR and BCR in PCa patients after radical prostatectomy. Two studies by Sharam V and Lee H revealed that patients with higher NLRs experienced BCR significantly sooner. The remaining two studies by Zhang G M and Young Suk identified a similar but not significant trend. However, a significant, albeit modest, effect was observed after integration into our meta-analysis, with a 1.12-fold higher BCR after radical prostatectomy in patients with an elevated preoperational NLR (HR = 1.12, 95% CI: 1.02–1.21) (Fig 2B) (Table 1).

**NLR and OS in PCa**

Fourteen studies reported a correlation between pre-treatment NLR and OS in PCa patients. Two independent cohorts were included in the studies of R.J. Van et al and Sonpavde G et al; we labeled these cohorts R.J Van/TAX327, R.J Van/VENICE, Sonpavde G 1, and Sonpavde 2. Thus, a total of 16 cohorts were included in the OS analysis.

For the overall population, a random (I–V) analysis was selected due to heterogeneity (I² = 60.0%, P = 0.001). The pooled HR of 1.40 (95% CI: 1.25–1.55) indicates that patients with elevated NLRs are expected to have shorter OS (Fig 2E) (Table 1).
Fig 1. Flow chart outlining the study selection process.

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097

For more information, visit www.prisma-statement.org.
In the subgroup analysis based on ethnicity, an elevated NLR appeared to be a stronger predictor of risk in Asian patients than Caucasian patients, with HRs of 2.25 (95% CI: 1.08–3.41) and 1.39 (95% CI: 1.24–1.53), respectively (Table 2). When the patients were stratified by status, an elevated NLR was significantly associated with OS in mCRPC and LPC patients, with HRs of 1.45 (95% CI: 1.32–1.59) and 1.12 (95% CI: 1.01–1.23), respectively (Table 2). Further subgroup analysis based on cut-off value (NLR ≥ 5: HR = 1.40, 95% CI: 1.15–1.66 VS. NLR < 5: HR = 1.41, 95% CI: 1.21–1.62) and sample size (n > 300: HR = 1.39, 95% CI: 1.23–1.56, vs. n < 300: HR = 1.43, 95% CI: 1.11–1.74) produced similar results (Table 2).

NLR and PFS in CRPC

Six cohorts exhibited an association between an elevated NLR and PFS in CRPC. The pooled-effect estimates (HR = 1.42, 95% CI: 1.23–1.61) indicated a significant correlation between an elevated pre-treatment NLR and worse PFS in CRPC (Table 1)(Fig 2C).

NLR and RFS in LPC after radical prostatectomy

Seven studies documented RFS data. Two of these studies reported that the NLR was a significant prognostic indicator, whereas the remaining studies did not observe a notable association between an elevated NLR and shorter RFS. However, our meta-analysis of these studies indicated a significant correlation between these factors, with a pooled HR of 1.38 (95% CI: 1.01–1.75, I² = 79.2%, p = 0.00) (Table 1, Fig 2D) under the random-effects model.

**Extensive statistical analysis.** To verify the above results obtained using Stata, another analysis was conducted using generic inverse variance method via Revman 5.3. Fig 3 showed similar results in PSARS, BCR, OS, RFS, and PFS analysis when generic inverse variance method was employed in Revman.

**Publication bias and heterogeneity evaluation**

Begg’s funnel plot and Egger’s test were employed to assess the overt publication bias in each meta-analysis in this study. Publication biases were identified in the OS analysis by Egger’s test (p > |t| = 0.002) and in the PSARS analysis with Pr > |Z| = 0.024 by Begg’s funnel plot and p > |t| = 0.013 by Egger’s test. We applied “trim and fill” analysis to identify the source of the publication bias. It was estimated that there were five unpublished studies evaluating the role of the NLR in OS (S1A Fig) and three unpublished studies evaluating the role of NLR in PSARS (S1B Fig). The results of the filled meta-analysis that combined estimated unpublished studies correlated well with our primary pooled results with a pooled HR = 1.40 (95% CI: 1.25–1.57) for the NLR and OS and a pooled OR = 1.71 (95% CI: 1.46–2.01) for the NLR and PSARS. No obvious publication biases were detected in the other analyses.
Fig 2. Forest plot and meta-analysis of studies evaluating the association between an elevated NLR and PSARS (A), BCR (B), PFS (C), RFS (D), OS (E).

doi:10.1371/journal.pone.0158770.g002
Sensitivity analysis indicated that the majority of the heterogeneity in the OS analysis was contributed by the studies by Bahig H et al. and Sharma et al. (S2A Fig). The main source of heterogeneity in these two studies was the presentation of data from univariate analysis. After excluding these studies, the corresponding pooled HR of 1.46 (95% CI: 1.36–1.56) was not significantly altered and exhibited no obvious heterogeneity (I² = 13.1%, p = 0.31), indicating the reliability of the results. Subgroup analysis performed as an additional sensitivity test also indicated the source of heterogeneity. Statistical methods (univariate analysis) were also the major contributor of heterogeneity in the RFS analysis (S2B Fig).

**Discussion**

In the present study, we utilized 18,092 cases from 22 related studies to evaluate the prognostic role of the NLR in PCa. To the best of our knowledge, this is the first meta-analysis to investigate the relationship between an elevated NLR and PSARS, BCR. The results indicated that an elevated NLR was a mild risk factor for BCR in PCa patients after radical prostatectomy. Furthermore, we determined that an elevated NLR was a strong predictor of PSARS in mCRPC patients. An elevated NLR predicted worse OS, PFS, and RFS, in contrast to the results of a previous meta-analysis by Yin et al. These authors found that an elevated NLR was significantly associated with OS in mCRPC but not LPC. However, our analysis included more studies and thus more available evidence with less heterogeneity, and we demonstrated that an elevated NLR was significantly associated with OS not only in mCRPC but also in LPC. By contrast, a lower risk was observed in localized LPC.

A significant association between an elevated NLR and RFS in LPC was identified that was not reported in the previous study. The prognostic value of the NLR has been demonstrated in many malignancies[38–40]. An elevated NLR may be associated with both an increased neutrophil-dependent systemic inflammatory response and a lower lymphocyte-mediated antitumor immune response, reflecting a supportive tumor microenvironment[41,42]. Neutrophils are the predominant leukocyte subset in human peripheral blood and play an important role in tumor development by producing cytokines, proteases, and reactive oxygen species (ROS) and interacting with other immune cells[9]. Tumor-associated neutrophils can favor genetic instability via the release of ROS, promote tumor cell proliferation via elastase, sustain angiogenesis via the release of vascular endothelial growth factor (VEGF), enhance neoplastic cell invasiveness by secreting hepatocyte growth factor (HGF), oncostatin M (OSM)[43], and matrix metalloproteinase 9 (MMP-9), and suppress effective antitumor CD8+ T cell immunity via arginase expression[44]. By contrast, lymphocytes are critical components of antitumor immunity. CD8+ T lymphocytes, which recognize endogenous intracellular antigens presented by MHC class I molecules, are directly capable of killing tumor cells[45]. CD4+ T lymphocytes are
Fig 3. Forest plot and meta-analysis of studies evaluating the association between an elevated NLR and PSARS (A), BCR (B), PFS (C), RFS (D), OS (E).

doi:10.1371/journal.pone.0158770.g003
central to immune system functions and play a vital role in tumor immunity. CD4⁺ T lymphocytes (also known as helper T lymphocytes) recognize antigens presented by MHC class II molecules, assist cytotoxic CD8⁺ T cells, and aid antibody production by B lymphocytes, thereby increasing the efficiency of tumor destruction[46]. Moreover, CD4⁺ T cells can directly or indirectly lyse tumor cells[46]. In addition to their antibody production capacity, B lymphocytes are involved in tumor surveillance by boosting T lymphocyte responses, serving as local antigen-presenting cells, and forming tertiary lymphoid structures in mutual cooperation with T cells and dendritic cells[47].

Recently, emerging studies have identified a heterogeneous population of myeloid-derived suppressor cells (MDSCs) that suppress tumour immunity responses and consequently significantly impede anti-cancer therapies. MDSCs are not a defined subset of myeloid cells, but rather a heterogeneous population of myeloid progenitor cells and immature myeloid cells[48]. In pathological conditions, such as cancer, MDSCs are expanded and activated by various factors produced by tumour cells and/or by stromal cells in the tumour microenvironment[48]. C. M. Diaz-Montero et al found that the percent and absolute number of MDSCs are significantly increased in the peripheral blood of patients with a range of solid tumours, including prostate cancer, than healthy volunteers[49]. More recently, two studies demonstrated that the CSF1R[50] and IL-6[51] pathways play critical roles in the migration of MDSCs to tumours microenvironments. MDSCs suppress tumour immunity mainly through its remarkable ability to suppress T-cell responses. Extensive studies have detailed how MDSCs mediated suppression of T-cell function through the release of enzymes (arginase 1 and iNOS), reactive oxygen species and peroxynitrite[48]. Furthermore, MDSCs also indirectly mediate T-cell function by inducing T regulatory cells[48]. In addition to suppressing T cells, MDSCs also perturb tumour immunity in regulating macrophages and nature kill cells[52].

Hypothetically, the combined index of the elevated NLR likely reflects a favorable immune microenvironment for tumor development and metastasis. However, the exact mechanisms underlying the elevation in the NLR and the unfavorable outcomes are unknown. First, some T lymphocyte subsets have both pro- and antitumor properties. For example, CD4⁺ T lymphocytes can be further divided into TH1 cells, TH2 cells, TH17 cells and regulatory T cells. TH17 cells and regulatory T cells promote tumor progression. Because the NLR is a relative parameter, whether the increase in the NLR is due to a relative increase in neutrophils or decrease in lymphocytes is unclear. Importantly, changes in the lymphocyte subsets were not defined. Consequently, the NLR is an approximate index with heterogeneity that reflects the immune microenvironment for tumor development, which may explain the inconsistent results of the included studies. More specific NLR (e.g., NLCD4TH2R, NLCD4TH17R, and NLBR) indices should be explored to generate more precise predictions in future studies. Second, tumors are often infiltrated by various numbers of immune cells, which are also involved in cancer progression. However, the process of circulating immune cell recruitment to the tumor is not clear. Whether intra-tumor neutrophils are recruited from the bone marrow/blood pool of neutrophils or the spleen is unknown[53]. Moreover, neutrophils may influence the recruitment and differentiation of macrophages by releasing various cytokines[53].

Immune cells infiltrating prostate cancer tissues may be influenced by the tumor environment to facilitate PCa progression, which adds another level of complexity to the mechanisms of these cells in cancer development. Abundant immune cells have been detected in prostate tumor tissues by immunohistochemistry using different markers (CD3⁺, CD8⁺, CD20⁺, CD56⁺, CD68⁺ and Foxp3⁺)[54]. One study demonstrated that patients with very low and very high CD3⁺ T cell numbers had shorter BCR survival than patients with intermediate numbers of T cells; however, no significant association was identified when CD20 was used to mark B lymphocytes in the same patients[55]. Nora Ness et al. reported that the infiltration of high
densities of CD8⁺ lymphocytes into prostate tumor epithelial areas was an independent risk factor for BCR [56]. Kiniwa et al. determined that regulatory T cells (CD8⁺ Foxp3⁺ or CD4⁺ CD25⁺) present in prostate tumors mediate immunosuppression by suppressing naïve T cell proliferation[57]. Furthermore, Vincenzo et al. revealed that cytotoxic T lymphocytes that infiltrated in the prostate tumor were immunosuppressed by substances secreted in the tumor microenvironment[58].

The potential of NLR to predict PSARS in response to drug treatments in mCRPC patients has been studied extensively, but less is known about the mechanisms. In our meta-analysis, a high NLR was associated with a low PSARS to chemotherapy but not ASI, thus suggesting that mCRPC patients with an elevated NLR may receive greater benefit from chemotherapy than ASI. Here, we hypothesize that different tumor immune environments after treatment with chemotherapy or ASI may be a contributing factor and subsequently affect the effectiveness of the treatments. Supporting this hypothesis, an increase in the relative densities of CD3⁺ and CD8⁺ T lymphocytes as well as CD68⁺ macrophages was observed under androgen depletion treatment compared to radical prostatectomy[54]. Additionally, NLR has been positively associated with PSA in men without prostatic disease[30] as well as with PCa[59]. McDonald et al. proposed that the NLR reflects the balance between innate (neutrophils) and adaptive (lymphocytes) immune responses; therefore, its association with higher serum PSA levels may indicate impairment in the adaptive host’s ability to control inflammation[30]. This finding may indicate that ASIs are more dependent on adaptive immune cells to fulfill their therapeutic effectiveness compared to chemotherapy.

Future studies should investigate the functions of specific subsets of neutrophils and lymphocytes due to the complex roles of immune cells in cancer development. This approach may facilitate the identification of new anticancer therapies or improve the effectiveness of existing treatments. The relationship between circulating immune cells and tumor-infiltrating immune cells is another vital problem. The mechanisms by which immune cells are recruited into tumor tissues to promote tumor progression should also be considered as therapeutic targets. The mechanisms underlying an elevated NLR and the response to anticancer treatment should also be explored. Such studies would facilitate the selection of patients who are more lost likely to benefit from drugs developed for mCRPC.

Our study has several limitations that should be carefully considered. First, studies lacking sufficient survival data for the meta-analysis were excluded. Second, the number of relevant studies was not sufficient to obtain a robust conclusion in some endpoint analyses. Another limitation of this study is the variety of NLR cut-off values employed in related studies. Further prospective studies are needed to confirm these conclusions.

**Conclusion**

In conclusion, this meta-analysis provides evidence that an elevated NLR predicts lower PSARS after chemotherapy and poor survival outcomes in PCa. These two inexpensive and easily accessible indicators can help stratify high-risk patients and guide therapy choices. Future studies should seek to identify more specific NLRs for consistent and precise predictions. A greater understanding of the mechanisms underlying the role of the NLR in PCa progression will facilitate the development of new anticancer strategies.

**Supporting Information**

S1 Fig. Funnel plot adjusted with trim and fill method. A: Trim and Fill analysis of NLR and OS; B: Trim and Fill analysis of NLR and PSARS. Circles: included studies. Diamonds:
presumed missing studies.

(TIF)

S2 Fig. Heterogeneity resource evaluation. A: Sensitive analysis of NLR and OS; B: Sensitive analysis of NLR and RFS.

(TIF)

S1 File. PRISMA 2009 checklist.

(DOC)

S2 File. Cover letter from Nature Publication Group language edition team for the first edition of this manuscript.

(PDF)

S3 File. Marked-up copy after edited by Nature Publication Group language edition team.

(DOCX)

S1 Table. Characteristics of all studies.

(XLS)

Acknowledgments

We acknowledge all patients included in this study.

Author Contributions

Conceived and designed the experiments: RX XKZ. Performed the experiments: JC XZ. Analyzed the data: JC XFL XZ. Wrote the paper: JC XFL.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a cancer J Clin. 2015; 65: 87–108. doi:10.3322/caac.21262

2. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol. 2008; 9: 445–452. doi:10.1016/S1470-2045(08)70104-9 PMID: 18424233

3. Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136: E359–86. doi:10.1002/ijc.29210 PMID: 25220842

4. Potosky AL, Kessler L, Gridley G, Brown CC, Horn JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. JNatlCancer Inst. 1990; 82: 1624–1628.

5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273: 548–552. doi: 10.1001/jama.273.7.548 PMID: 7530782

6. Li J, Djennaba JA, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer. 2012; 2012: 691380. doi: 10.1155/2012/691380 PMID: 23251806

7. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, et al. Guidelines on Prostate Cancer. Update. 2011; 53: 31–45. doi: 10.1016/j.eururo.2007.09.002

8. Pezzaro C, Woo HH, Davis ID. Prostate cancer: Measuring PSA. Intern Med J. 2014; 44: 433–440. doi: 10.1111/imj.12407 PMID: 24816306

9. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. Elsevier Inc.; 2010; 140: 883–899. doi: 10.1016/j.cell.2010.01.025 PMID: 20303879

10. Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer. Medicine (Baltimore). 2016; 95: 2544. doi: 10.1097/MD.0000000000002544

11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of Observational Studies. 2008; 283.
12. Tierney JF, Stewart LA, Gchersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. doi: 10.1186/1745-6215-8-16 PMID: 17555582

13. Sutton AJ, Abrams KR, Jones DR, Sheldon T a, Song F. Methods for Meta-analysis in Medical Research. 2000; 309.

14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188. 0197-2456(86)90046-2 [pii] PMID: 3802833

15. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56: 455–463. doi: 10.1111/j.0006-341x.2000.00455.x PMID: 10877304

16. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015; 26: 750–755. doi: 10.1093/annonc/mdu587 PMID: 25538172

17. Kwon YS, Han CS, Yu JW, Kim S, Modi P, Davis R, et al. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clin Genitourin Cancer. Elsevier Inc.; 2015; 1–8. doi: 10.1016/j.clgc.2015.07.018

18. Chung CH. Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy. Oncologist. 2008; 13: 725–732. doi: 10.1634/theoncologist.2008-0012 PMID: 18586928

19. Zhang J, Wang HT, Yang Q, Du J, Jia WY. castration-resistant prostate cancer treated with docetaxel-based chemotherapy. TUMOUR. 2015; 35: 333–339. doi: 10.3781/j.issn.1000-7431.2015.33.707

20. Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2014; 114: E11–E17. doi: 10.1111/bju.12531 PMID: 24529213

21. Zhang G-M, Zuo Y, Ma X-C, Qin X-J, Wan F-N, Dai B, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio. Medicine (Baltimore). 2015; 94: e1473. doi: 10.1097/MD.0000000000001473

22. Yao A, Seijima T, Iwamoto H, Masago T, Morizane S, Honda M, et al. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015; 22: 827–833. doi: 10.1111/iju.12839 PMID: 26087772

23. Sümbül AT, Sezer A, Abali H, Köse F, Gültepe I, Mertsoyulu H, et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 2014; 1–5. doi: 10.1007/s11255-014-0664-7

24. van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, et al. Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2014; 2014: 743–749. doi: 10.1093/annonc/mdu569

25. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. Nature Publishing Group; 2012; 15: 195–201. doi: 10.1038/pcan.2011.60 PMID: 22343838

26. Poyet C, Adank A, Keller E, Morotezavi A, Rabgang T, Pfister B, et al. Mp66-05 Pretreatment Systemic Inflammatory Response Parameters Do Not Predict the Outcome in Men With Prostate Cancer Undergoing Radical Prostatectomy. J Urol. 2015; 193: e55. doi: 10.1016/j.juro.2015.02.252358

27. Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atanufo EG, Keizman D, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014; 25: 657–62. doi: 10.1093/annonc/mdt581 PMID: 24458472

28. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, et al. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. Elsevier Inc; 2014; 12: 317–324. doi: 10.1016/j.clgc.2014.03.005 PMID: 24806399

29. Sharma V, Cockerill PA, Viers BR, Rangel LJ, Carlson RE, Kamei R, et al. Mp6-05 the Association of Preoperative Neutrophil To Lymphocyte Ratio With Oncologic Outcomes Following Radical Prostatectomy for Prostate Cancer. J Urol. Elsevier Ltd; 2015; 193: e55–e56. doi: 10.1016/j.juro.2015.02.252

30. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostate disease—the 2001–2008 National Health and Nutrition Examination Survey. Prostate. 2014; 74: 561–7. doi: 10.1002/pros.22782 PMID: 24435840

31. Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
32. Proctor MJ, Morrison DS, Taiwar D, Balmer SM, Fletcher CD, O’Reilly DSJ, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. Elsevier Ltd; 2011; 47: 2633–2641. doi: 10.1016/j.ejca.2011.03.028 PMID: 21724383

33. Lee H, Jeong SJ, Hong SK, Byun S-S, Lee SE, Oh JJ. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol. 2015; doi: 10.1007/s00345-015-1701-6

34. Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014; 120: 3346–3352. doi: 10.1002/cncr.28890 PMID: 24995769

35. Minardi D, Scartozzi M, Montesi L, Santoni M, Burattini L, Bianconi M, et al. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. Springerplus. Springer International Publishing; 2015; 4: 255. doi: 10.1186/s40064-015-1036-1 PMID: 26085975

36. McLachlan JM, Chan DL, Crumbaker MA, Marx GM. Neutrophil-to-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer. Cancer Treat Commun. Elsevier; 2015; 4: 81–85. doi: 10.1016/j.ctc.2015.06.001

37. Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer. BMC Cancer; 2015; 15: 594. doi: 10.1186/s12885-015-1599-9 PMID: 26292807

38. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: A meta-analysis. PLoS One. 2014; 9. doi: 10.1371/journal.pone.0092079

39. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Journal of the National Cancer Institute. 2014. doi: 10.1093/jnci/dju124

40. Li M-X, Liu X-M, Zhang X-F, Zhang J-F, Wang W-L, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014; 134: 2403–13. doi: 10.1002/ijc.28536 PMID: 24122750

41. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, et al. IL-17-producing tumor-infiltrating myeloid cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015; 522: 345–8. doi: 10.1038/nature14282 PMID: 25822788

42. Piccard H, Muschel RJ, Opedenakker G, Tazzyman S, Niaz H, Murdoch C, et al. Neutrophil-mediated tumour angiogenesis: Subversion of immune responses to promote tumour growth. Semin Cancer Biol. 2013; 23: 149–158. doi: 10.1016/j.semcancer.2011.06.004 PMID: 23410638

43. Li XF, Chen DP, Ouyang FZ, Chen MM, Wu Y, Kuang DM, et al. Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma. J Hepatol. 2015; 62: 131–139. doi: 10.1016/j.jhep.2014.08.023 PMID: 25152203

44. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. Elsevier GmbH.; 2013; 218: 1402–62. doi: 10.1002/ijc.28536 PMID: 24122750

45. Ramanathan S, Gagnon J, Ilangumaran S. Antigen-nonspecific activation of CD8+ T lymphocytes by γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015; 522: 345–8. doi: 10.1038/nature14282 PMID: 25822788

46. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4+ T cells. Curr Opin Immunol. 2009; 21: 200–208. doi: 10.1016/j.coi.2009.02.004 PMID: 19285848

47. Zhang Y, Elav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, et al. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 2013; 62: 87–99. doi: 10.1007/s00262-013-1313-6 PMID: 22772949

48. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9: 162–74. doi: 10.1038/nri2506 PMID: 19197294

49. Díaz-Montero CM, Salem ML, Nishimura M, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009; 58: 49–59. doi: 10.1007/s00262-008-0523-4 PMID: 18446337

50. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013; 73: 1–13. doi: 10.1158/0008-5472.CAN-12-3981
51. Wu C Te, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med. 2012; 90: 1343–1355. doi: 10.1007/s00109-012-0916-x PMID: 22660275

52. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182: 4499–4506. doi: 10.4049/jimmunol.0802740 PMID: 19342621

53. Kim J, Bae J, Tam M. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. 2016; 2016. doi: 10.1155/2016/6058147 PMID: 26966341

54. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson A-M, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. Elsevier B.V.; 2009; 348: 9–17. doi: 10.1016/j.jim.2009.06.004 PMID: 19552894

55. Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012; 120: 901–8. doi: 10.1111/j.1600-0463.2012.02924.x PMID: 23009114

56. Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate. 2014; 74: 1452–1461. doi: 10.1002/pros.22862 PMID: 25111810

57. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007; 13: 6947–6958. doi: 10.1158/1078-0432.CCR-07-0842 PMID: 18056169

58. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005; 201: 1257–1268. doi: 10.1084/jem. 20042028 PMID: 15824085

59. Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer. BMC Cancer; 2016; 16: 111. doi: 10.1186/s12885-016-2134-3 PMID: 26883640